See today's BioWorld
To read the full story, subscribe or sign in.

Scohia secures entry into greater China market with Huadong agreement

June 7, 2021
By Gina Lee
Scohia Pharma Inc. has secured an agreement with Huadong Medicine Co. Ltd., enabling the former to tap the greater China market for SCO-094, its GLP-1R and GIPR dual agonist.
BioWorld Deals and M&A Diabetes Endocrine/metabolic Obesity China